STOCKS TELEGRAPH

Tag: NASDAQ: IMMP

  • Is that why Immutep Limited (NASDAQ: IMMP) is booming and glooming in the Post-market hours?

    Is that why Immutep Limited (NASDAQ: IMMP) is booming and glooming in the Post-market hours?

    Immutep Limited (NASDAQ: IMMP) stock surged 62% to touch $3.4 in the late-hours trading after, a biotech company that explores novel immunotherapy therapies for cancer and autoimmune diseases, confirmed report that EOC Pharma, its Chinese partner, will launch a new Phase II clinical trial in China for up to 152 patients with metastatic breast cancer.

    A randomized, double-blind, placebo-controlled phase II clinical study with study endpoints like progression-free survival, overall survival, and overall response rate would be the EOC Pharma trial, close to Immutep’s AIPAC study. It is planned to take place across 24 months across 20 clinical trial sites in China and test Immutep’s lead candidate medication eftilagimod alpha in conjunction with paclitaxel in patients with HER2-negative/HR-positive metastatic breast cancer who have progression following endocrine therapy.

    The Chinese authoritative body, the Chinese National Medical Goods Administration, has obtained positive technical guidance from EOC Pharma, causing the first patient to be enrolled and dosed in the trial in Q1 of the calendar year 2021.

  • Market Sentiment Mixed but there are Winners

    Market Sentiment Mixed but there are Winners

    The markets are headed to a mixed start to the week. The S&P 500 and the Dow are both in the red with the NASDAQ up marginally. The subdued sentiment is a reflection of activity in the European markets. Stocks in Europe are in the red as data shows a resurgence in COVID-19 cases. Essentially, this means that the world, including the U.S, is yet to fully control the pandemic.

    For the markets, this means a prolonged period of uncertainty and economic weakness. The Federal Reserve has already announced that it was projecting that the COVID-19 would continue to have a negative impact on the economy in the foreseeable future. Investors are looking to a future where subdued economic activity could potentially lead to a correction.

    Nonetheless, the U.S economy continues to show resilience. Even without an economic stimulus package from the government, the U.S economy continues to show signs of recovery in September.  This is an indicator that the underlying fundamentals are strong and that a new stimulus package or a COVIDD-19 vaccine could reignite the economy.

    In this environment of cautious optimism, there are stocks that are outperforming the market by a huge margin. In today’s session, some of the stocks showing signs of a major upside when markets open are as below:

    Immutep Limited [NASDAQ: IMMP]

    Immutep Limited is one of the top performers this morning and is up by close to 20%. This follows the company’s announcement of an improvement in results from stage 1 of its phase 2 TACTI-002 study. The company’s CMO Dr Fredric Triebel stated that by combining efti and pembrolizumab had shown good progress in people with HNSCC and NSCLC. The progress also attracted positive comments from external players. Commenting on it, principal investigator Dr Martin Forster of the University College London Hospital stated the results they received were encouraging.

    ClearOne Inc [NASDAQ: CLRO]

    This is another top performer this morning and is up by over 10%. This comes days after the company announced that it had priced $5.3 million direct offerings as per NASDAQ rule. The company announced that it would use money from the placement as working capital and other corporate purposes.

    Pivotal Investment Corporation II [NYSE: PIC]

    Pivotal Investment Corporation is another top performer this morning and is up by over 20% pre-market. This follows the company’s announcement that it was merging with XL Fleet, a commercial vehicle electrification company for listing on the NYSE. It is an interesting merger given XL’s growing demand and growing revenues.